Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Sarah R Curran"'
Autor:
Carrie E. Bearden, Marianne Bernadette van den Bree, Samuel J.R.A. Chawner, Leila Kushan, Louise Gallagher, Jeremy Hall, Wendy R. Kates, Kevin M. Antshel, Joanne L. Doherty, Judith S Miller, Caitlin C. Clements, Hayley Moss, Goran Cuturilo, A. Maillard, Raquel E. Gur, Sarah R Curran, LeeAnne Green-Snyder, Tara L. Wenger, Wendy K Chung, Michael J Owen, Richard Anney, Jacob Vorstman, Robert T. Schultz, Milica Pejovic-Milovancevic, Robin P. Goin-Kochel, Sébastien Jacquemont, Ellen Hanson, D M McDonald-McGinn, Raphael Bernier, Marina Mihaljevic, Ania M Fiksinski
Objective: Certain copy number variants (CNVs) greatly increase the risk of autism. The authors conducted a genetics-first study to investigate whether heterogeneity in the clinical presentation of autism is underpinned by specific genotype-phenotype
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2a71567fba7bdaac36b3b97eefed4c8
Publikováno v:
Lally, J, Gaughran, F, Timms, P & Curran, S R 2016, ' Treatment-resistant schizophrenia : Current insights on the pharmacogenomics of antipsychotics ', Pharmacogenomics and Personalized Medicine, vol. 9, pp. 117-129 . https://doi.org/10.2147/PGPM.S115741
Pharmacogenomics and Personalized Medicine
Pharmacogenomics and Personalized Medicine
Up to 30% of people with schizophrenia do not respond to two (or more) trials of dopaminergic antipsychotics. They are said to have treatment-resistant schizophrenia (TRS). Clozapine is still the only effective treatment for TRS, although it is under
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec5d6283648f8a7db3c1bc8d61767ec8
https://doi.org/10.2147/pgpm.s115741
https://doi.org/10.2147/pgpm.s115741
